Median effect analysis of efficacy versus adverse effects of immunosuppressants

Clinical Pharmacology and Therapeutics

Volumn 70, Issue 1, 2001, Pages 74-81

  Kahan, Barry D ^a,b   Kramer, William G ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b Kramer Consulting LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; PLACEBO; PREDNISONE; RAPAMYCIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

ACUTE DISEASE; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GRAFT REJECTION; HUMANS; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY TRANSPLANTATION; SIROLIMUS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0034927093     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2001.116309     Document Type: Article

References (34)

1. Update for the Canadian multicentre trial of cyclosporine in renal allografts
2. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in the prevention of rejection
3. Criteria for analyzing interactions between biologically active agents
4. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
5. Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro
6. The immunosuppressive antagonism of low doses of FK506 and cyclosporine
7. Synergistic effect of 15-deoxyspergualin and cyclosporine in prolonging survival of rat cardiac allografts
8. Synergistic interaction between castanospermine and tacrolimus in the rat heart allograft model
9. Effect of combination schedules of leflunomide
10. Beneficial effect of graft perfusion with anti-T cell receptor monoclonal antibodies on survival of small bowel allografts in rat recipients treated with brequinar alone or in combination with cyclosporine and sirolimus
11. Blocking of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities
12. Synergistic interaction of 3 M KCl-extracted donor antigens (e-HAg) with cyclosporine or cyclosporine/sirolimus for prolongation of rat heart allograft survival
13. A mammalian protein targeted by G1-arresting rapamycin-receptor complex
14. The side effect profile of sirolimus: A phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients
15. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine
16. Prolongation by rapamycin of heart, kidney, pancreas, and small bowel allograft survival in rats
17. Synergistic mechanisms by which sirolimus and cyclosporine inhibit rat heart and kidney allograft rejection
18. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation
19. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: A phase II trial
20. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts
21. Sirolimus (Rapamune, rapamycin) is more effective than azathioprine to reduce the incidence of acute renal allograft rejection episodes when used in combination with cyclosporine and prednisone: A phase III U.S. multicenter trial
22. Overview: Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters
23. Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants
24. An immunoassay for the measurement of sirolimus
25. Predicting glomerular filtration rate after kidney transplantation
26. International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology
27. Three-drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-alpha A
28. Computerized quantitation of synergism and antagonism of taxol, topotecan and cisplatin against teratocarcinoma cell growth: A rational approach to clinical protocol design
29. Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats
30. Relative tissue distributions of cyclosporine and sirolimus after concomitant peroral administration to the rat: Evidence for pharmacokinetic interactions
31. The effects of relative timing of sirolimus and cyclosporine co-administration on the pharmacokinetics of each agent
32. Effects of cyclosporine therapy on plasma lipoprotein levels
33. Center-specific graft and patient survival rates